手术时使用的局部血管扩展剂对DIEP动脉血管功能的持久影响
Jason S Kofoed1, Fatma B Tuncer2, Alvin C Kwok2
1Department of Nutrition and Integrative Physiology, University of Utah, Salt Lake City, Utah.
Journal of reconstructive microsurgery
|July 22, 2024
概括
在微血管外科手术中使用的局部帕帕维林和维拉帕米尔可以长期损害动脉功能,与利多卡因不同. 这项研究有助于外科医生选择更安全的血管扩展剂,以防止血管持续损伤.
科学领域:
- 血管外科 血管外科
- 药理学 药理学是指药理学的学科.
- 心血管研究研究心血管研究
背景情况:
- 外科医生通常在微血管手术期间使用局部帕帕维林,利多卡因和维拉帕米尔进行血管扩张.
- 人们担心这些药物在急性作用减弱后可能引起的术后内皮和光滑肌功能障碍.
研究的目的:
- 研究帕帕维林,利多卡因和维拉帕米尔对人体深下腹膜穿孔动脉血管扩张功能的持续作用.
- 在这些局部药物的急性血管扩张作用消失后评估血管功能.
主要方法:
- 从12名患者获得了人体深下部上胃动脉样本.
- 动脉环用帕帕维林,利多卡因,维拉帕米尔或盐水 (对照) 进行化,随后进行2小时的洗期.
- 使用异面张力测量了内皮依赖 (乙胆) 和独立 (酸) 的血管松.
主要成果:
- 与对照组相比,帕帕维林和维拉帕米尔显著降低了乙胆诱导的血管松.
- 利多卡因没有显著改变乙胆诱导的血管松.
- 在对照组,利多卡因组和维拉帕米尔组之间没有观察到酸胺诱导的血管松的显著差异,尽管帕帕维林显示出功能减弱的趋势.
结论:
- 帕帕维林和维拉帕米尔的手术剂量,但不是利多卡因,会对动脉血管扩张功能产生持久的负面影响.
- 这些发现表明,利多卡因可能是微血管外科手术中局部血管扩张的首选选择,以避免长期血管功能障碍.
相关概念视频
Antihypertensive Drugs: Vasodilators
495
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
495
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
142
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
142
Local Anesthetics: Pharmacokinetics
754
The potency and duration of action of local anesthetics (LAs) are determined by their pharmacokinetics. Pharmacokinetics describes how LAs are absorbed, distributed, metabolized, and eliminated from the body. When administered to the vascular tissues, LAs are quickly absorbed and enter the systemic circulation, reducing their localized effects. Adding vasoconstrictors such as epinephrine to LAs reduces their absorption into the systemic circulation, making them clinically effective. The...
754


